Skip to main content
. Author manuscript; available in PMC: 2014 Mar 1.
Published in final edited form as: Parasite Immunol. 2013 Mar;35(3-4):109–119. doi: 10.1111/pim.12019

Figure 3. PS-targeting treatment does not alter amastigote uptake by DCs.

Figure 3

BMDCs were co-cultured with different amounts of lesion-derived, CFSE-labeled amastigotes that were pre-treated with 9 μg/ml of mAb mch1N11 (αPS). (A, B) After 24h of infection, BMDCs were harvested, stained for CD11c, and subjected to FACS analysis. Numbers in the dot plots indicate the percentage of CFSE+, CD11c+ BMDCs. (B) Graph represents data from 3 independent experiments.